期刊文献+

使用超纯透析液对慢性血液透析患者血清瘦素和胰岛素样生长因子-1的影响 被引量:1

The effects of ultrapure dialysate on serum leptin and insulin growth fator-1 in chronic hemodialysis patients
下载PDF
导出
摘要 目的观察使用超纯透析液对慢性血液透析患者血清瘦素和胰岛素样生长因子-1的影响。方法长期血液透析患者21例,随机分为超纯透析液和常规透析液组,均用低通量聚砜膜透析器,前瞻性观察两组入组前1周、入组后1周、1月、6月和12月透析前干体重、血白蛋白、血清瘦素和胰岛素样生长因子-1(IGF-1),以及nPCR和Kt/V有无差异。结果至12月观察结束,超纯透析组患者干体重、nPCR、Kt/V、血白蛋白、血清瘦素较常规透析液组的变化均没有差异。在治疗12月后,超纯透析组IGF-1较其基线明显升高(配对t检验P<0.05),但是与对照组的变化相比,没有差异。结论使用超纯透析液应有益于改善慢性血液透析患者的营养状况。 Objective The aim was to observe the effects of ultrapure dialysate (UPD) on nutritional parameters in chronic hemodialysis patients. Methods A controlled, prospective and randomized study was carried out on 21 stable patients dialyzed on low-flux synthetic polysulphone membrane and assigned to either UPD or conventional dialysate (CD). Blood samples and dialysate samples were collected at pre-dialysis. The variables monitored included Kt/V, normalized protein catabolic rate (nPCR), dry body weight, serum albumin, serum leptin and IGF-1. They were measured one week before the study, and after one week, one month, six months and twelve months during the dialysis session. Results There were no significant differences in the changes of Kt/V, nPCR, dry body weight, serum albumin and serum leptin between the two groups. At the end of study, there was a significant increase of IGF-1 in UPD group (paired t test, P 〈 0.05), as compared with their baseline values. However, there was no difference in the changes of IGF-1 between the two groups. Conclusions Use of UPD should be beneficial to the nutritional status in long-term hemodialysis patients.
出处 《中国血液净化》 2009年第8期420-422,共3页 Chinese Journal of Blood Purification
关键词 超纯透析液 血液透析 胰岛素样生长因子-1 瘦素 Ultrapure dialysate Hemodialysis Leptin Insulin growth factor-1
  • 相关文献

参考文献13

  • 1Charles C, Guy L , Bernard C, et al. Malnutrition in longterm haemodialysis survivors[J]. Nephrol Dial Transplant, 2001, 16: 61-69.
  • 2Chen KH, Lin-Tan DT, Huang WH, et al. Cardiothoracic ratio, malnutrition, inflammation, and two-year mortality in non-diabetic patients on maintenance hemodialysis [J]. Kidney Blood Press Res, 2008, 31:143-151.
  • 3Amore A, Coppo R. Immunological basis of inflammation in dialysis[J]. Nephrol Dial Transplant, 2002, 17 Suppl 8: 16-24.
  • 4Schiffl H, Lang SM, Stratakis D, et al. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters[J]. Nephrol Dial Transplant, 2001, 16:1863- 1869.
  • 5Ward RA. Ultrapure dialysate[J]. Semin Dial, 2004, 17: 489-497.
  • 6Matsuhashi N, Yoshioka T. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients [J]. Nephron, 2002, 92:601-604.
  • 7Lamas JM, Alonso M, Sastre F, et al. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements--a randomized study[J]. Nephrol Dial Transplant, 2006, 21:2851-2858.
  • 8Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid[J]. Artif Organs, 1999, 23:37-43.
  • 9Ward RA. Ultrapure dialysate: a desirable and achievable goal for routine hemodialysis[J]. Semin Dial, 2000,13: 378-380.
  • 10Bommer J, Jaber BL. Ultrapure dialysate: facts and myths [J]. Semin Dial, 2006, 19:115-119.

二级参考文献16

  • 1Amore A, Coppo R. Immunological basis of inflammation in dialysis[J]. Nephrol Dial Transplant, 2002,17 Suppl 8:16-24.
  • 2Lonnemann G. Chronic inflammation in hemodialysis: the role of contaminated dialysate[J]. Blood Purif ,2000,18:214-223.
  • 3Ward RA. Ultrapure dialysate[J]. Semin Dial, 2004, 17:489-497.
  • 4Ward RA. Ultrapure dialysate: a desirable and achievable goal for routine hemodialysis[J]. Semin Dial, 2000,13:378-380.
  • 5Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid[J]. Artif Organs, 1999,23:37-43.
  • 6Song M, Kellum JA. Interleukin-6[J]. Crit Care Med, 2005,33:S463- S465.
  • 7Panichi V, Migliori M, De PS, et al. Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitudinal clinical survey[J]. Blood Purif, 2000,18:30-36.
  • 8Webb AT, Reaveley DA, O'Donnell M, et al. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy[J]. Nephrol Dial Transplant, 1995,10:354-357.
  • 9Miyata T, Oda O, lnagi R, et al. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis- associated amyloidosis[J]. J Clin Invest, 1993,92:1243-1252.
  • 10Schouten WE. Grooteman ME van Houte AJ, et al. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis [J]. Nephrol Dial Transplant. 2000,15:379-384.

共引文献5

同被引文献9

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部